Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics reported Q2 revenue of $13.8 million, up 38% year-over-year, driven by manufacturing and royalty revenue, while reaffirming full-year revenue guidance of $46 million to $50 million. The company successfully completed the required human factors validation and pharmacokinetic studies for Anaphylm and remains on track to resubmit the NDA to the FDA in the third quarter of 2026.
Key figures
- Revenue
- 13800000
- Guidance
- FY2026 Total revenue $46M-$50M; Non-GAAP adjusted EBITDA loss $35M-$30M
- Revenue Yoy
- 38%
- Cash
- 98500000
- Shares outstanding
- 125511648
- Manufacturing supply revenue
- 11900000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.